Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021, with a specific reporting date of April 12, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) rather than a financial performance report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £13.1380 per share.
- Transaction Volumes: 38 shares and 33 shares in separate transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate acquisitions of ordinary shares by company executives on April 9, 2021, executed on the London Stock Exchange (XLON). These acquisitions were the result of dividend reinvestment plans on shares held within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of PDMR transactions.
Key Facts for Investor Verification
- Transaction Type: Both transactions were automatic acquisitions via dividend reinvestment, not open market purchases.
- Executives Involved: Mr. D Redfern (Chief Strategy Officer) and Ms. V Whyte (Company Secretary).
- Transaction Date: April 9, 2021.
- Dividend Reference: Transactions followed dividends paid to shareholders on April 8, 2021.
- Volume: The total number of shares acquired by these two individuals in this filing is 71.